Agen wins D-dimer patent case against Innogenetics
This article was originally published in Clinica
Executive Summary
Australian biotechnology company Agen claims that a European patent decision in its favour has opened the door to further development of its D-dimer blood clotting marker. The European patent court in Munich found for Agen and against Innogenetics, without recourse for further appeal from the losing company, strengthening Agen's patent position worldwide.